Tweet
Emerg Infect Dis
. 2022 Mar 8;28(5).
doi: 10.3201/eid2805.220271. Online ahead of print.
Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
Pinkus Tober-Lau, Henning Gruell, Kanika Vanshylla, Willi M Koch, David Hillus, Philipp Schommers, Isabelle Suárez, Norbert Suttorp, Leif Erik Sander, Florian Klein, Florian Kurth
- PMID: 35259088
- DOI: 10.3201/eid2805.220271
Abstract
To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.
Keywords: 2019 novel coronavirus disease; B cell; COVID-19; SARS-CoV-2; coronavirus disease; immunity; mRNA; neutralizing antibody; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.